Literature DB >> 16731946

Dissociation of a MAVS/IPS-1/VISA/Cardif-IKKepsilon molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3-4A proteolytic cleavage.

Rongtuan Lin1, Judith Lacoste, Peyman Nakhaei, Qiang Sun, Long Yang, Suzanne Paz, Peter Wilkinson, Ilkka Julkunen, Damien Vitour, Eliane Meurs, John Hiscott.   

Abstract

Intracellular RNA virus infection is detected by the cytoplasmic RNA helicase RIG-I that plays an essential role in signaling to the host antiviral response. Recently, the adapter molecule that links RIG-I sensing of incoming viral RNA to downstream signaling and gene activation events was characterized by four different groups; MAVS/IPS-1-1/VISA/Cardif contains an amino-terminal CARD domain and a carboxyl-terminal mitochondrial transmembrane sequence that localizes to the mitochondrial membrane. Furthermore, the hepatitis C virus NS3-4A protease complex specifically targets MAVS/IPS-1/VISA/Cardif for cleavage as part of its immune evasion strategy. With a novel search program written in python, we also identified an uncharacterized protein, KIAA1271 (K1271), containing a single CARD-like domain at the N terminus and a Leu-Val-rich C terminus that is identical to that of MAVS/IPS-1/VISA/Cardif. Using a combination of biochemical analysis, subcellular fractionation, and confocal microscopy, we now demonstrate that NS3-4A cleavage of MAVS/IPS-1/VISA/Cardif/K1271 results in its dissociation from the mitochondrial membrane and disrupts signaling to the antiviral immune response. Furthermore, virus-induced IKKepsilon kinase, but not TBK1, colocalized strongly with MAVS at the mitochondrial membrane, and the localization of both molecules was disrupted by NS3-4A expression. Mutation of the critical cysteine 508 to alanine was sufficient to maintain mitochondrial localization of MAVS/IPS-1/VISA/Cardif and IKKepsilon in the presence of NS3-4A. These observations provide an outline of the mechanism by which hepatitis C virus evades the interferon antiviral response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731946      PMCID: PMC1472616          DOI: 10.1128/JVI.02495-05

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Triggering the interferon antiviral response through an IKK-related pathway.

Authors:  Sonia Sharma; Benjamin R tenOever; Nathalie Grandvaux; Guo-Ping Zhou; Rongtuan Lin; John Hiscott
Journal:  Science       Date:  2003-04-17       Impact factor: 47.728

Review 2.  Toll-like receptor signalling.

Authors:  Shizuo Akira; Kiyoshi Takeda
Journal:  Nat Rev Immunol       Date:  2004-07       Impact factor: 53.106

3.  Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20.

Authors:  Rongtuan Lin; Long Yang; Peyman Nakhaei; Qiang Sun; Ehssan Sharif-Askari; Ilkka Julkunen; John Hiscott
Journal:  J Biol Chem       Date:  2005-11-23       Impact factor: 5.157

4.  IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts.

Authors:  Sarah M McWhirter; Katherine A Fitzgerald; Jacqueline Rosains; Daniel C Rowe; Douglas T Golenbock; Tom Maniatis
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-16       Impact factor: 11.205

Review 5.  CARD proteins as therapeutic targets in cancer.

Authors:  Jason S Damiano; John C Reed
Journal:  Curr Drug Targets       Date:  2004-05       Impact factor: 3.465

6.  An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.

Authors:  Daniel Lamarre; Paul C Anderson; Murray Bailey; Pierre Beaulieu; Gordon Bolger; Pierre Bonneau; Michael Bös; Dale R Cameron; Mireille Cartier; Michael G Cordingley; Anne-Marie Faucher; Nathalie Goudreau; Stephen H Kawai; George Kukolj; Lisette Lagacé; Steven R LaPlante; Hans Narjes; Marc-André Poupart; Jean Rancourt; Roel E Sentjens; Roger St George; Bruno Simoneau; Gerhard Steinmann; Diane Thibeault; Youla S Tsantrizos; Steven M Weldon; Chan-Loi Yong; Montse Llinàs-Brunet
Journal:  Nature       Date:  2003-10-26       Impact factor: 49.962

7.  The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.

Authors:  Mitsutoshi Yoneyama; Mika Kikuchi; Takashi Natsukawa; Noriaki Shinobu; Tadaatsu Imaizumi; Makoto Miyagishi; Kazunari Taira; Shizuo Akira; Takashi Fujita
Journal:  Nat Immunol       Date:  2004-06-20       Impact factor: 25.606

8.  Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture.

Authors:  Keril J Blight; Jane A McKeating; Joseph Marcotrigiano; Charles M Rice
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

9.  The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection.

Authors:  Hiroaki Hemmi; Osamu Takeuchi; Shintaro Sato; Masahiro Yamamoto; Tsuneyasu Kaisho; Hideki Sanjo; Taro Kawai; Katsuaki Hoshino; Kiyoshi Takeda; Shizuo Akira
Journal:  J Exp Med       Date:  2004-06-21       Impact factor: 14.307

10.  Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection.

Authors:  Andrea K Perry; Edward K Chow; Julia B Goodnough; Wen-Chen Yeh; Genhong Cheng
Journal:  J Exp Med       Date:  2004-06-21       Impact factor: 14.307

View more
  109 in total

1.  IκB kinase ε-dependent phosphorylation and degradation of X-linked inhibitor of apoptosis sensitizes cells to virus-induced apoptosis.

Authors:  Peyman Nakhaei; Qiang Sun; Mayra Solis; Thibault Mesplede; Eric Bonneil; Suzanne Paz; Rongtuan Lin; John Hiscott
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Alternative ferritin mRNA translation via internal initiation.

Authors:  Alina Daba; Antonis E Koromilas; Kostas Pantopoulos
Journal:  RNA       Date:  2012-01-23       Impact factor: 4.942

3.  A functional C-terminal TRAF3-binding site in MAVS participates in positive and negative regulation of the IFN antiviral response.

Authors:  Suzanne Paz; Myriam Vilasco; Steven J Werden; Meztli Arguello; Deshanthe Joseph-Pillai; Tiejun Zhao; Thi Lien-Anh Nguyen; Qiang Sun; Eliane F Meurs; Rongtuan Lin; John Hiscott
Journal:  Cell Res       Date:  2011-01-04       Impact factor: 25.617

4.  Herpes simplex virus 1 tegument protein US11 downmodulates the RLR signaling pathway via direct interaction with RIG-I and MDA-5.

Authors:  Junji Xing; Shuai Wang; Rongtuan Lin; Karen L Mossman; Chunfu Zheng
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

5.  Varicella-zoster virus immediate-early protein ORF61 abrogates the IRF3-mediated innate immune response through degradation of activated IRF3.

Authors:  Huifang Zhu; Chunfu Zheng; Junji Xing; Shuai Wang; Shuping Li; Rongtuan Lin; Karen L Mossman
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

6.  Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus.

Authors:  Masaki Mibayashi; Luis Martínez-Sobrido; Yueh-Ming Loo; Washington B Cárdenas; Michael Gale; Adolfo García-Sastre
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 7.  Regulation of hepatic innate immunity by hepatitis C virus.

Authors:  Stacy M Horner; Michael Gale
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

8.  The acidic domain of hepatitis C virus NS4A contributes to RNA replication and virus particle assembly.

Authors:  Tung Phan; Andrew Kohlway; Peniel Dimberu; Anna Marie Pyle; Brett D Lindenbach
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

Review 9.  Innate antiviral immune signaling, viral evasion and modulation by HIV-1.

Authors:  Arjun Rustagi; Michael Gale
Journal:  J Mol Biol       Date:  2013-12-08       Impact factor: 5.469

10.  Herpes simplex virus 1 serine/threonine kinase US3 hyperphosphorylates IRF3 and inhibits beta interferon production.

Authors:  Shuai Wang; Kezhen Wang; Rongtuan Lin; Chunfu Zheng
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.